X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7016) 7016
Magazine Article (23) 23
Book Chapter (10) 10
Web Resource (6) 6
Publication (5) 5
Conference Proceeding (4) 4
Book / eBook (2) 2
Book Review (1) 1
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6699) 6699
ticlopidine - analogs & derivatives (5705) 5705
ticlopidine - therapeutic use (5236) 5236
platelet aggregation inhibitors - therapeutic use (4744) 4744
male (3741) 3741
female (3381) 3381
clopidogrel (2903) 2903
middle aged (2898) 2898
aspirin - therapeutic use (2815) 2815
aged (2713) 2713
aspirin (2048) 2048
cardiac & cardiovascular systems (1865) 1865
treatment outcome (1813) 1813
drug therapy, combination (1523) 1523
ticlopidine - adverse effects (1448) 1448
platelet aggregation inhibitors - adverse effects (1332) 1332
ticlopidine - administration & dosage (1237) 1237
percutaneous coronary intervention (1156) 1156
risk factors (1129) 1129
stents (1063) 1063
platelet aggregation inhibitors - administration & dosage (1041) 1041
peripheral vascular disease (1024) 1024
platelet aggregation - drug effects (923) 923
ticlopidine (914) 914
antiplatelet therapy (877) 877
adult (875) 875
pharmacology & pharmacy (821) 821
ticlopidine - pharmacology (802) 802
time factors (796) 796
risk (782) 782
hematology (775) 775
abridged index medicus (764) 764
acute coronary syndromes (746) 746
platelet aggregation inhibitors - pharmacology (746) 746
prospective studies (725) 725
medicine, general & internal (712) 712
thrombosis (702) 702
aged, 80 and over (693) 693
aspirin - administration & dosage (692) 692
myocardial-infarction (681) 681
acute coronary syndrome - drug therapy (678) 678
anticoagulants - therapeutic use (667) 667
aspirin - adverse effects (637) 637
stroke (636) 636
therapy (630) 630
drug therapy (624) 624
angioplasty, balloon, coronary (618) 618
follow-up studies (595) 595
blood platelets - drug effects (576) 576
retrospective studies (549) 549
myocardial infarction - drug therapy (548) 548
cardiovascular (542) 542
coronary heart disease (533) 533
care and treatment (527) 527
heart attacks (523) 523
prevention (517) 517
hemorrhage - chemically induced (508) 508
cardiology (491) 491
prasugrel (490) 490
cardiac patients (486) 486
blood platelets (484) 484
randomized controlled trials as topic (467) 467
fibrinolytic agents - therapeutic use (465) 465
mortality (460) 460
stroke - prevention & control (456) 456
trial (456) 456
adenosine - analogs & derivatives (447) 447
intervention (434) 434
thrombosis - prevention & control (433) 433
thiophenes - therapeutic use (432) 432
platelet function tests (426) 426
drug interactions (422) 422
prasugrel hydrochloride (418) 418
surgery (413) 413
analysis (410) 410
aggregation (408) 408
animals (393) 393
risk assessment (389) 389
stent (388) 388
angioplasty (383) 383
clinical trials as topic (383) 383
drug resistance (381) 381
secondary prevention (380) 380
drug-eluting stents (375) 375
acute coronary syndrome (373) 373
coronary angiography (373) 373
outcomes (373) 373
coronary artery disease - drug therapy (372) 372
acute myocardial-infarction (365) 365
double-blind method (365) 365
medicine & public health (364) 364
purinergic p2y receptor antagonists - therapeutic use (364) 364
inhibition (361) 361
cardiovascular disease (354) 354
clinical neurology (352) 352
adenosine - therapeutic use (351) 351
platelets (347) 347
recurrence (343) 343
stent thrombosis (340) 340
platelet reactivity (337) 337
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6488) 6488
German (190) 190
French (116) 116
Russian (90) 90
Spanish (89) 89
Japanese (72) 72
Chinese (57) 57
Italian (57) 57
Polish (20) 20
Dutch (16) 16
Turkish (13) 13
Portuguese (12) 12
Hungarian (10) 10
Danish (7) 7
Ukrainian (7) 7
Korean (6) 6
Finnish (5) 5
Hebrew (4) 4
Czech (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Romanian (2) 2
Swedish (2) 2
Croatian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
..., and such findings have prompted efforts to seek new therapeutic strategies. 10 – 15 Two new promising approaches have emerged to reduce the risk of bleeding among patients... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 359, Issue 7, pp. 677 - 687
Journal Article
Drugs, ISSN 0012-6667, 2004, Volume 64, Issue 15, pp. 1657 - 1670
The US FDA has approved two drugs for the management of intermittent claudication: pentoxifylline and cilostazol. The mechanism of action that provides symptom... 
Cilostazol, therapeutic use | Fibroblast growth factor gene therapy, therapeutic | Prostaglandins, therapeutic use | Naftidrofuryl, therapeutic use | Pentoxifylline, therapeutic use | Arginine, therapeutic use | Policosanol, therapeutic use | Ticlopidine, therapeutic use | Research and development | Buflomedil, therapeutic use | Vascular endothelial growth factor, therapeutic us | Intermittent claudication, treatment | Fibroblast growth factor 2, therapeutic use | Glutathione, therapeutic use | Sulodexide, therapeutic use | Vascular endothelial growth factor gene therapy, t | Ginkgo biloba leaf extract, therapeutic use | Levocarnitine, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | ANTIPLATELET AGENT | DOUBLE-BLIND | CAMP-PHOSPHODIESTERASE INHIBITOR | PHARMACOLOGY & PHARMACY | PROPIONYL-L-CARNITINE | TOXICOLOGY | QUALITY-OF-LIFE | GROWTH-FACTOR | GENE-TRANSFER | PERIPHERAL ARTERIAL-DISEASE | THERAPEUTIC ANGIOGENESIS | Vasodilator Agents - therapeutic use | Humans | Intermittent Claudication - drug therapy | Treatment Outcome | Clinical Trials as Topic | Pentoxifylline - adverse effects | Pentoxifylline - therapeutic use | Animals | Tetrazoles - administration & dosage | Tetrazoles - therapeutic use | Tetrazoles - adverse effects | Vasodilator Agents - adverse effects | Pentoxifylline - administration & dosage | Vasodilator Agents - administration & dosage
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 08/2004, Volume 110, Issue 9, pp. 1061 - 1068
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10081, pp. 1799 - 1808
Summary Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | MANAGEMENT | MYOCARDIAL-INFARCTION | TICAGRELOR | STENT THROMBOSIS | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | INTERVENTION | SECONDARY PREVENTION | ANTIPLATELET THERAPY | Purinergic P2Y Receptor Antagonists - administration & dosage | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Myocardial Infarction - diagnostic imaging | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Coronary Angiography - methods | Adenosine - therapeutic use | Thrombolytic Therapy - methods | Ticlopidine - administration & dosage | Female | Myocardial Infarction - physiopathology | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Electrocardiography - methods | Purinergic P2Y Receptor Antagonists - therapeutic use | Rivaroxaban - therapeutic use | Double-Blind Method | Treatment Outcome | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Drug Therapy, Combination - methods | Factor Xa Inhibitors - therapeutic use | Myocardial Infarction - drug therapy | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Medical research | Medical colleges | Aspirin | Mortality | Cardiac patients | Clinical trials | Medicine, Experimental | Dosage and administration | Research institutes | France | Coronary heart disease | Analysis | Myocardial infarction | Therapy | Angiography | Disorders | Angina | Evidence-based medicine | Bleeding | Randomization | Motivation | Atherosclerosis | Safety | Drug therapy | Drug dosages | Heart diseases | Anticoagulants | Research & development--R&D | Strata | Coronary artery | Patients | Thrombosis | Thrombolysis | Inhibitors | Arteriosclerosis | Biomarkers | Infarction | Acute coronary syndromes
Journal Article
European heart journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | REDUCTASE INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ABCB1 | GENETIC-VARIANTS | CYP2C19 | CYTOCHROME-P450 3A4 | CLINICAL PHARMACOGENETICS | DRUG-DRUG INTERACTION | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
Archives of gerontology and geriatrics, ISSN 0167-4943, 2012, Volume 55, Issue 1, pp. 148 - 151
Abstract Older people tend to have multiple comorbid conditions and subsequent polypharmacy, which place them at higher risk of adverse drug events, drug–drug... 
Internal Medicine | Potentially inappropriate medication | Polypharmacy | Potential prescribing omission | Elderly | Inappropriate prescribing | ADMISSIONS | POPULATION | BEERS CRITERIA | ALERT DOCTORS | OUTPATIENTS | CARE | GERIATRICS & GERONTOLOGY | PEOPLE | STOPP SCREENING TOOL | PRESCRIPTIONS | DRUG-DRUG INTERACTIONS | Metformin - therapeutic use | Prevalence | Ticlopidine - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Inappropriate Prescribing - statistics & numerical data | Male | Medication Errors - statistics & numerical data | Ticlopidine - analogs & derivatives | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Histamine H1 Antagonists - therapeutic use | Antipsychotic Agents - therapeutic use | Hospitals - statistics & numerical data | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Taiwan - epidemiology | Aged, 80 and over | Female | Aged | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Benzodiazepines - therapeutic use | Heart failure | Type 2 diabetes | Drugs | Enzymes | Antihistamines | Hospital patients | Chemical inhibitors | Prescription writing | Diabetes in old age | Risk factors | Benzodiazepines | Prescribing | Blood circulation disorders | Tranquilizing drugs | Antipsychotic drugs | Enzyme inhibitors | Angiotensin converting enzyme | Angiotensin | Insulin resistance | Diabetes | Metformin | Antianxiety agents | Statins
Journal Article